Synthetic analog · 11 amino acids · 1,257.3 Da

Cibinetide (ARA-290) studies and research data

PepBank has 63 ARA-290 studies with results. 56 of them gave ARA-290, with 366 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 366 results and 97 papers. Newer studies from Europe PMC

Results in people

10% of 366 results

Results in animals

243

66% of 366 results

Results in lab cells

24% of 366 results

From computer models

0% of 366 results

The molecule

ARA-290 identity

Identifiers, parent molecule, targets and development stage, from curated data.

Cibinetide, research code ARA-290, is an 11-residue peptide that copies the water-facing side of helix B of erythropoietin. Brines and colleagues reported in 2008 that this surface carries the tissue-protective activity of erythropoietin, which is mediated by a receptor heterocomplex of the erythropoietin receptor and CD131 (the innate repair receptor), while red-cell production is mediated by the erythropoietin receptor homodimer; the peptide is not erythropoietic in vitro or in vivo. Araim Pharmaceuticals developed it for small nerve fibre loss in sarcoidosis and for islet transplantation, with orphan designations in the United States and the European Union. Development has reached phase 2.

Kind: Synthetic analog · 11 residues
Identifiers: ChEMBLCHEMBL3545305 (opens in a new tab)PubChem CID91810664 (opens in a new tab)UNII9W5677JKDA (opens in a new tab)DrugBankDB13006 (opens in a new tab)CAS1208243-50-8KEGGD11218 (opens in a new tab)IUPHAR9677 (opens in a new tab)
Parent: Analog of Erythropoietin (human)Designed from the three-dimensional structure of erythropoietin, not cut from its sequence. Brines et al. 2008 report that helix B (residues 58-82) faces the aqueous medium when erythropoietin is bound to the receptor homodimer and that an 11-residue peptide built from the amino acids forming that aqueous face is tissue protective and not erythropoietic. A substring check against the mature EPO chain confirms the cibinetide sequence is not contiguous in EPO.
Development: Phase 2Araim Pharmaceuticals, Inc.ChEMBL records max_phase 2. Four ClinicalTrials.gov records, only the first sponsored by Araim: NCT02039687 (phase 2, corneal nerve fibre density and neuropathic symptoms in sarcoidosis, Araim Pharmaceuticals, 64 participants, 2014-01 to 2015-02, completed; published as Culver et al. 2017, PMID 28475703), NCT02070783 (phase 1/2, cognitive and neural effects, Leiden University Medical Center, 36 participants, 2012-02 to 2014-02, completed), NCT01933529 (phase 2, prediabetes and type 2 diabetes, Claes-Göran Östenson, 24 participants, 2013-10 to 2015-12, status unknown) and NCT06626971 (phase 2, diabetic macular oedema, Belfast Health and Social Care Trust, 9 participants, 2016-04 to 2017-08, terminated). No ClinicalTrials.gov record with a start date after 2017 was found. The current status of Araim Pharmaceuticals was not confirmed. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Innate repair receptor (erythropoietin receptor and CD131 heterocomplex), EPOR subunitEPORP19235 (opens in a new tab)	Agonist	ChEMBL mechanismSource (opens in a new tab)
Innate repair receptor (erythropoietin receptor and CD131 heterocomplex), CD131 subunitCSF2RBP32927 (opens in a new tab)	Agonist	ChEMBL mechanismSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

11 amino acids · 1 modification

EQLERALNS

-OH

Alignment to Erythropoietin (human)

Calculated from the two sequences. Curated notes are shown as given.

4 of 11 aligned residues identical (36%) · 6 substitutions · 1 non-canonical residue · Erythropoietin (human) 9–19

Top row: Erythropoietin (human) (parent)
Bottom row: Cibinetide (ARA-290)

LER

Same as parent
Substituted
Non-canonical or D-form
Added
Gap
Modified side chain or end
Parent context

Differences from the parent

1Parent 9 · analog 1Ser → pGlu · Non-canonical residueL-pyroglutamyl (5-oxo-L-proline) at the N terminus. ChEMBL writes it as [Glp] in the HELM; GSRS notes the protein spelling XEQLERALNSS.
2Parent 10 · analog 2Arg → Glu · Substitution
3Parent 11 · analog 3Val → Gln · Substitution
4Parent 15 · analog 7Tyr → Ala · Substitution
5Parent 17 · analog 9Leu → Asn · Substitution
6Parent 18 · analog 10Glu → Ser · Substitution
7Parent 19 · analog 11Ala → Ser · Substitution

Basis: Designed from the three-dimensional structure of erythropoietin, not cut from its sequence. Brines et al. 2008 report that helix B (residues 58-82) faces the aqueous medium when erythropoietin is bound to the receptor homodimer and that an 11-residue peptide built from the amino acids forming that aqueous face is tissue protective and not erythropoietic. A substring check against the mature EPO chain confirms the cibinetide sequence is not contiguous in EPO.

Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.

Properties

From identity sources

Formula: C₅₁H₈₄N₁₆O₂₁
Molecular weight: 1,257.3 g/mol
Monoisotopic mass: 1,256.5997 Da

GSRS UNII 9W5677JKDA(opens in a new tab)retrieved 2026-10-09
PubChem CID 91810664(opens in a new tab)retrieved 2026-10-09
ChEMBL CHEMBL3545305(opens in a new tab)retrieved 2026-10-09
UniProt P01588(opens in a new tab)retrieved 2026-10-09

Calculated from the sequence

pKa set

Some values cannot be calculated. The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Average mass: Not calculated
Monoisotopic mass: Not calculated
Isoelectric point (pI): Not calculated
Net charge at pH 7.4: Not calculated
GRAVY (hydropathy): Not calculated
Extinction coefficient, 280 nm (Cys reduced): 0 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp or Tyr: absorbance at 280 nm cannot measure this peptide.
Instability index: Not calculated
Aliphatic index: Not calculated
Boman index: Not calculated
Hydrophobic moment (μH): Not calculated

1 non-canonical residue (X) is not included in calculated values.
The N-terminal group is not modeled.
Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

No charge curve

The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Composition

Hydrophobic27% (3)A L
Positive9% (1)R
Negative18% (2)E
Polar36% (4)N Q S
Non-canonical9% (1)X

11 residues. Each residue counts in one class; F and W count as aromatic.

A Ala1 · 9%

I Ile0 · 0%

L Leu2 · 18%

M Met0 · 0%

V Val0 · 0%

F Phe0 · 0%

W Trp0 · 0%

Y Tyr0 · 0%

H His0 · 0%

K Lys0 · 0%

R Arg1 · 9%

D Asp0 · 0%

E Glu2 · 18%

N Asn1 · 9%

Q Gln1 · 9%

S Ser2 · 18%

T Thr0 · 0%

C Cys0 · 0%

G Gly0 · 0%

P Pro0 · 0%

X Xaa1 · 9%

3D structure

PredictedAlphaFold DB · P01588

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 91810664(opens in a new tab)

C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.608
μH, best 11-residue window: —
Arrow direction: 305°
Residues: 11 · 1 X not scored

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	X	0°	not scored
2	E	100°	-0.74
3	Q	200°	-0.85
4	L	300°	1.06
5	E	40°	-0.74
6	R	140°	-2.53
7	A	240°	0.62
8	L	340°	1.06
9	N	80°	-0.78
10	S	180°	-0.18
11	S	280°	-0.18

Results by area

ARA-290 results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

63 of 97 studies have results (65%), published 2011 to 2026. Top row: every study. Bottom row: studies with results about Cibinetide (ARA-290), by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies97 in all, 1999 to 2026

Studies with results63 in all, 2011 to 2026

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

ARA-290 studies on brain and nerves

39 results · people 7 · animals 24 · lab 8

Top 5 of 39 results

In people with sarcoidosis nerve fiber loss, 1 mg a day of cibinetide did not clearly change corneal nerve fiber area compared with placebo.Investigative ophthalmology & visual science, 2017
In diabetic rats, pHBSP reduced a stress response of supporting cells in the retina compared with scrambled peptide.Diabetes, 2011
In adults with type 2 diabetes and low corneal nerve fiber density, nerve fibers increased with ARA‑290 and did not change with placebo.Molecular medicine, 2015
In diabetic rats, pHBSP reduced DNA damage in the retina compared with scrambled peptide.Diabetes, 2011
In people with sarcoidosis nerve fiber loss, 4 mg a day of cibinetide increased corneal nerve fiber area compared with placebo.Investigative ophthalmology & visual science, 2017

ARA-290 studies on pain

20 results · people 6 · animals 14 · lab 0

Top 3 of 20 results

In people with sarcoidosis nerve pain, pain improved in all groups; the abstract does not say whether cibinetide did better than placebo.Investigative ophthalmology & visual science, 2017
In people with sarcoidosis and nerve symptoms, ARA‑290 improved a nerve symptom score at week 4 more than placebo did.Molecular medicine, 2012
In adults with type 2 diabetes, nerve pain symptoms improved more in the ARA‑290 group.Molecular medicine, 2015

ARA-290 studies on eyes

8 results · people 6 · animals 2 · lab 0

Top 3 of 8 results

In people with diabetic macular edema, some, but not all, had better retinal thickness, tear production, diabetes control and urine protein after cibinetide.Journal of clinical medicine, 2020
In people with diabetic macular edema, 12 weeks of cibinetide did not improve best corrected vision compared with the start.Journal of clinical medicine, 2020
In people with diabetic macular edema, 12 weeks of cibinetide did not improve retinal thickness compared with the start.Journal of clinical medicine, 2020

ARA-290 studies on mood, stress and behavior

6 results · people 5 · animals 1 · lab 0

Top 3 of 6 results

In healthy adults, one week after ARA290, brain responses to happy faces were lower than with placebo.European neuropsychopharmacology, 2015
In people with sarcoidosis and nerve symptoms, depression symptom scores did not change with ARA‑290.Molecular medicine, 2012
In healthy adults, ARA290 tended to lower recognition of happy faces compared with placebo, but the result was only a trend.European neuropsychopharmacology, 2015

ARA-290 studies on memory and thinking

10 results · people 3 · animals 7 · lab 0

Top 3 of 10 results

In healthy adults, ARA290 did not improve memory for positive words compared with placebo.European neuropsychopharmacology, 2015
In healthy adults, ARA290 was linked to faster sorting of positive and negative words than placebo.European neuropsychopharmacology, 2015
In healthy adults, ARA290 increased attention to positive pictures compared with placebo.European neuropsychopharmacology, 2015

ARA-290 studies on side effects

9 results · people 3 · animals 6 · lab 0

Top 4 of 9 results

In people with sarcoidosis and nerve symptoms, tests and checks raised no safety concerns with ARA‑290 in this small study.Molecular medicine, 2012
In mice, ARA290 did not cause movement or behavior side effects, in both normal mice and mice lacking the β-common receptor.PloS one, 2013
In people with diabetic macular edema, no serious side effects were seen during 12 weeks of cibinetide.Journal of clinical medicine, 2020
In adults with type 2 diabetes, no potential safety issues were identified with ARA‑290 in this phase 2 study.Molecular medicine, 2015

ARA-290 studies on daily life and fitness

3 results · people 2 · animals 1 · lab 0

3 results

In people with sarcoidosis and nerve symptoms, the ARA‑290 group had a clear change from baseline in a physical function quality-of-life score.Molecular medicine, 2012
In people with sarcoidosis and nerve symptoms, tiredness scores improved about equally with ARA‑290 and with placebo.Molecular medicine, 2012
In rats with mild brain injury, pHBSP did not change movement ability compared with the inactive control peptide.Journal of neurotrauma, 2013

ARA-290 studies on immune system and inflammation

118 results · people 1 · animals 84 · lab 33

Top 5 of 118 results

In people with diabetic macular edema, no antibodies against cibinetide were found after 12 weeks of treatment.Journal of clinical medicine, 2020
In rats with nerve inflammation, ARA290 did not change levels of the inflammation signal CCL2, compared with vehicle.Neuroscience, 2013
In rats with mild brain injury, pHBSP reduced the activation of inflammatory cells in the brain.Journal of neurotrauma, 2013
In rats with severe blood loss, pHBSP reduced inflammation in the lungs.Molecular medicine, 2011
In pigs with kidney injury, ARA290 showed a trend toward lower MCP-1, an inflammation signal, compared with saline.Journal of translational medicine, 2013

ARA-290 studies on blood sugar

25 results · people 1 · animals 19 · lab 5

Top 5 of 25 results

In adults with type 2 diabetes, people given ARA‑290 had improved HbA1c, a long-term blood sugar marker, over 56 days.Molecular medicine, 2015
In diabetic mice with transplanted islets, ARA‑290 improved blood glucose levels compared with control animals.Transplantation, 2016
In mice that received human islets, cibinetide treatment led to more human insulin in the liver than in controls.Cell transplantation, 2021
In mice fed a high-fat diet, pHBSP improved insulin resistance.Scientific reports, 2015
In mice that received human islets, cibinetide treatment led to higher human C-peptide in the blood than in controls.Cell transplantation, 2021

ARA-290 studies on cholesterol and blood fats

1 result · people 1 · animals 0 · lab 0

1 result

In adults with type 2 diabetes, people given ARA‑290 had improved blood fat profiles over 56 days.Molecular medicine, 2015

ARA-290 studies on kidneys and bladder

29 results · people 0 · animals 21 · lab 8

Top 3 of 29 results

In pigs with kidney injury, ARA290 raised kidney filtering rate over seven days, compared with saline.Journal of translational medicine, 2013
In rats with severe blood loss, pHBSP reduced kidney injury.Molecular medicine, 2011
In mice with lupus, ARA290 eased kidney inflammation symptoms.Journal of cellular and molecular medicine, 2018

ARA-290 studies on skin, hair and wounds

27 results · people 0 · animals 17 · lab 10

Top 5 of 27 results

In diabetic mice, ARA290 on an elastin-like carrier sped up wound healing.Biomaterials, 2017
In mice with poor leg blood flow, one ARA290 injection plus cell transplant improved blood flow in the affected leg after 28 days.Shock, 2016
In mice with retinal ischemia, pretreating repair cells with ARA290 or EPO before delivery did not improve their vessel repair.Experimental eye research, 2019
In mice with burns, ARA290 kept small blood vessels in the wound open, while vehicle-treated wounds developed clots.Proceedings of the National Academy of Sciences of the United States of America, 2013
In mice with poor leg blood flow, one ARA290 injection plus cell transplant increased small blood vessel density after 28 days.Shock, 2016

ARA-290 studies on heart and blood vessels

17 results · people 0 · animals 17 · lab 0

Top 5 of 17 results

In rats with a heart attack, one injection of pHBP reduced cell death in the at-risk heart area, like erythropoietin did.Molecular medicine, 2011
In rats with a heart attack, pHBP limited enlargement of the heart's main chamber at two weeks, like erythropoietin.Molecular medicine, 2011
In aged rats, ARA290 reduced the age-related rise in blood pressure compared with saline.Frontiers in cardiovascular medicine, 2022
In rats with a preeclampsia-like condition, the peptide reduced a measure of blood vessel lining dysfunction.International journal of molecular sciences, 2020
In rats with a preeclampsia-like condition, the peptide improved blood flow in the placenta.International journal of molecular sciences, 2020

ARA-290 studies on receptors and cell signals

21 results · people 0 · animals 11 · lab 10

Top 5 of 21 results

In rats with severe blood loss, pHBSP reduced activation of NF-κB, a driver of inflammation.Molecular medicine, 2011
In mice, ARA290 changed NMDA receptor gene activity in a way similar to ketamine; the abstract does not say which way.PloS one, 2013
In rats with severe blood loss, pHBSP increased activation of endothelial nitric oxide synthase, an enzyme of blood vessels.Molecular medicine, 2011
In rats with severe blood loss, pHBSP increased activation of Akt, a cell-survival protein.Molecular medicine, 2011
In rats with a preeclampsia-like condition, the peptide improved the balance of two cell-death regulating proteins.International journal of molecular sciences, 2020

ARA-290 studies on bones and joints

6 results · people 0 · animals 5 · lab 1

Top 3 of 6 results

In female mice, one month of cibinetide raised the density of the outer bone layer.International journal of molecular sciences, 2021
In mice with apical periodontitis, ARA290 reduced the number of bone-resorbing cells near the tooth root.International dental journal, 2025
In female mice, one month of cibinetide raised the density of the inner spongy bone.International journal of molecular sciences, 2021

ARA-290 studies on survival and serious illness

5 results · people 0 · animals 5 · lab 0

5 results

In mice with colitis, cibinetide improved survival compared with solvent.Scientific reports, 2017
In mice with hemolytic-uremic syndrome, pHBSP improved survival over seven days.Frontiers in immunology, 2022
In rats with severe blood loss, pHBSP reduced nerve and muscle injury.Molecular medicine, 2011
In rats with severe blood loss, pHBSP reduced lung injury.Molecular medicine, 2011
In rats with severe blood loss, pHBSP reduced injury to the pancreas.Molecular medicine, 2011

ARA-290 studies on cells, genes and aging

11 results · people 0 · animals 4 · lab 7

Top 5 of 11 results

In aged rats, ARA290 increased the clearing of damaged material in heart muscle cells.Frontiers in cardiovascular medicine, 2022
In aged rats, ARA290 made heart cell mitochondria less sensitive to damage from oxidant stress.Frontiers in cardiovascular medicine, 2022
In lab cells, ARA290 reduced the DNA damage caused by the cancer drug doxorubicin, compared with doxorubicin alone.Toxicology in vitro, 2020
In cells, ARA290 switched on survival signals in endothelial colony-forming cells.Experimental eye research, 2019
In aged rats, ARA290 reduced build-up of an ageing pigment in heart cells.Frontiers in cardiovascular medicine, 2022

ARA-290 studies on weight and appetite

5 results · people 0 · animals 4 · lab 1

Top 4 of 5 results

In mice fed a high-fat diet, pHBSP improved obesity.Scientific reports, 2015
In mice with colitis, cibinetide improved weight gain compared with solvent.Scientific reports, 2017
In diabetic mice, ARA290 did not change body weight.Experimental neurology, 2011
In aged rats, ARA290 helped keep body weight compared with saline.Frontiers in cardiovascular medicine, 2022

ARA-290 studies on liver

1 result · people 0 · animals 1 · lab 0

1 result

In rats with severe blood loss, pHBSP reduced liver injury.Molecular medicine, 2011

ARA-290 studies on muscles and tendons

4 results · people 0 · animals 0 · lab 4

Top 3 of 4 results

In mouse muscle cells under simulated ischemia, ARA‑290 reduced the share of dying cells.Journal of vascular surgery, 2014
In muscle cells under simulated lack of blood flow, ARA‑290 improved cell function and survival compared with ischaemia alone.University College London, 2014
In mouse muscle cells under simulated ischemia, ARA‑290 lowered a marker of cell death.Journal of vascular surgery, 2014

ARA-290 studies on infections

1 result · people 0 · animals 0 · lab 1

1 result

In lab cells, ARA290 reduced how many E. coli bacteria entered bladder cells.FEMS immunology and medical microbiology, 2011

Trials and papers

ARA-290 trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

4 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (4 of 4)

4 trials · 2 completed · 1 stopped early · 1 with posted results

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

2012201320142015201620172018

Ph 1/2
CONEARA
NCT02070783
Feb 2012 to Feb 2014
Ph 2
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
NCT01933529
Oct 2013 to est. Dec 2015
Ph 2
Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
NCT02039687
Jan 2014 to Feb 2015
Ph 2
ARA290DMO
NCT06626971
Apr 2016 to Aug 2017
Terminated
Terminated

4 trials · 2 completed · 1 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 2NCT06626971

The Use of ARA290 for the Treatment of Diabetic Macular Oedema

Belfast Health and Social Care Trustn = 9Apr 2016 to Aug 2017

Diabetic Macular Oedema

Trial page ClinicalTrials.govUpdated 4 Oct 2024

CompletedPhase 2Results postedNCT02039687

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

Araim Pharmaceuticals, Inc.n = 64Jan 2014 to Feb 2015

Neuropathy of Sarcoidosis

Trial page ClinicalTrials.govUpdated 18 Apr 2017

Status unknownPhase 2NCT01933529

ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)

Claes-Göran Östensonn = 24Oct 2013 to est. Dec 2015

Diabetes Type 2 · Impaired Glucose Tolerance · Impaired Fasting Glucose

Trial page ClinicalTrials.govUpdated 3 Sept 2015

CompletedPhase 1/2NCT02070783

Cognitive and Neural Effects of ARA290

Leiden University Medical Centern = 36Feb 2012 to Feb 2014

Depression

Trial page ClinicalTrials.govUpdated 25 Feb 2014

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

97 studies match. Retracted studies are left out.

Showing 16 of 97 studiesquery qry_dd7e6459960dbcbd0438cbf3

Studies with results

63 studies in all, 15 on this page

Animal study (in vivo) · rat · 2011

7 results

Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy.

McVicar et al. 2011Diabetesn = 24cited by 98

PMID 21911748PMC3198080DOI 10.2337/db11-0026PUB-21911748

Free to read · publisher termsCC BY-NC-ND7 results where Cibinetide (ARA-290) was given

Read at source See results (7)

Other design · 2015

5 results

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

Brines et al. 2015Molecular medicine (Cambridge, Mass.)cited by 93

PMID 25387363PMC4365069DOI 10.2119/molmed.2014.00215PUB-25387363

CC BY5 results where Cibinetide (ARA-290) was given

Download PDF See results (5)

Randomized controlled trial · 2017

8 results

Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.

Culver et al. 2017Investigative ophthalmology & visual sciencen = 64cited by 79

PMID 28475703DOI 10.1167/iovs.16-21291PUB-28475703

CC BY8 results where Cibinetide (ARA-290) was given

Download PDF See results (8)

Randomized controlled trial · 2012

7 results

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

Heij et al. 2012Molecular medicine (Cambridge, Mass.)n = 22cited by 74

PMID 23168581PMC3563705DOI 10.2119/molmed.2012.00332PUB-23168581

CC BY7 results where Cibinetide (ARA-290) was given

Download PDF See results (7)

Animal study (in vivo) · mouse · 2017

6 results

Co-delivery of a growth factor and a tissue-protective molecule using elastin biopolymers accelerates wound healing in diabetic mice.

Devalliere et al. 2017Biomaterialscited by 67

PMID 28688286DOI 10.1016/j.biomaterials.2017.06.043PUB-28688286

Full text at the publisher3 results where Cibinetide (ARA-290) was given (plus 3 on tools or combinations, listed separately)

Publisher page See results (6)

In vitro (cells) · 2014

2 results

Immunosuppressive effects of erythropoietin on human alloreactive T cells.

Cravedi et al. 2014Journal of the American Society of Nephrology : JASNcited by 50

PMID 24676641PMC4147979DOI 10.1681/asn.2013090945PUB-24676641

Rights unknown2 results where Cibinetide (ARA-290) was given

Source link See results (2)

Animal study (in vivo) · mouse · 2013

4 results

Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns.

Bohr et al. 2013Proceedings of the National Academy of Sciences of the United States of Americacited by 48

PMID 23401545PMC3587271DOI 10.1073/pnas.1214099110PUB-23401545

Rights unknown4 results where Cibinetide (ARA-290) was given

Source link See results (4)

Animal study (in vivo) · mouse and rat · 2011

4 results

ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.

Swartjes et al. 2011Anesthesiologycited by 42

PMID 21873879DOI 10.1097/aln.0b013e31822fcefdPUB-21873879

Full text at the publisher4 results where Cibinetide (ARA-290) was given

Publisher page See results (4)

Animal study (in vivo) · rat · 2011

9 results

A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.

Ahmet et al. 2011Molecular medicine (Cambridge, Mass.)cited by 39

PMID 21170473PMC3060982DOI 10.2119/molmed.2010.00235PUB-21170473

Rights unknown9 results where Cibinetide (ARA-290) was given

Source link See results (9)

Not a test of Cibinetide (ARA-290) alone · 2016

22 results

Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.

Thomas et al. 2016Journal of separation sciencecited by 38

PMID 26578461DOI 10.1002/jssc.201501060PUB-26578461

Rights unknown3 results where Cibinetide (ARA-290) was a tool, carrier or part of a combination

Source link See results (22)

Animal study (in vivo) · rat · 2012

4 results

Neuroprotection with an erythropoietin mimetic peptide (pHBSP) in a model of mild traumatic brain injury complicated by hemorrhagic shock.

Robertson et al. 2012Journal of neurotraumacited by 36

PMID 21545288PMC4955612DOI 10.1089/neu.2011.1827PUB-21545288

Rights unknown4 results where Cibinetide (ARA-290) was given

Source link See results (4)

Animal study (in vivo) · pig · 2013

4 results

ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury.

van Rijt et al. 2013Journal of translational medicinen = 8cited by 32

PMID 23302512PMC3567997DOI 10.1186/1479-5876-11-9PUB-23302512

CC BY4 results where Cibinetide (ARA-290) was given

Download PDF See results (4)

Not a test of Cibinetide (ARA-290) alone · 2021

7 results

Multifaceted roles of a bioengineered nanoreactor in repressing radiation-induced lung injury.

Liu et al. 2021Biomaterialscited by 31

PMID 34478930DOI 10.1016/j.biomaterials.2021.121103PUB-34478930

Full text at the publisher7 results where Cibinetide (ARA-290) was a tool, carrier or part of a combination

Publisher page See results (7)

Animal study (in vivo) · rat · 2011

12 results

A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock.

Patel et al. 2011Molecular medicine (Cambridge, Mass.)cited by 29

PMID 21607291PMC3188881DOI 10.2119/molmed.2011.00053PUB-21607291

Rights unknown12 results where Cibinetide (ARA-290) was given

Source link See results (12)

Animal study (in vivo) · rat · 2014

6 results

ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.

Swartjes et al. 2014Molecular paincited by 28

PMID 24529189PMC3928087DOI 10.1186/1744-8069-10-13PUB-24529189

CC BY6 results where Cibinetide (ARA-290) was given

Download PDF See results (6)

More studies

10 studies in all, 1 on this page

PubMed tag: Randomized Controlled Trial · 2013

Corrected

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

Dahan et al. 2013Molecular medicine (Cambridge, Mass.)cited by 63

PMID 24136731PMC3883966DOI 10.2119/molmed.2013.00122PUB-24136731

CC BY

Download PDF Read the notice

No result for Cibinetide (ARA-290) (9 studies on this page, 24 in all)

These studies name Cibinetide (ARA-290) but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: none · 2018

Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy.

Brines et al. 2018Scientific reportscited by 76

PMID 29549285PMC5856845DOI 10.1038/s41598-018-23107-wPUB-29549285

CC BY

Download PDF

PubMed tag: Review · 2015

Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.

Collino et al. 2015Pharmacology & therapeuticscited by 67

PMID 25728128DOI 10.1016/j.pharmthera.2015.02.005PUB-25728128

Full text at the publisher

Publisher page

PubMed tag: none · 2013

Erythropoietin neuroprotection with traumatic brain injury.

Ponce et al. 2013Pathophysiology : the official journal of the International Society for Pathophysiologycited by 57

PMID 22421507PMC3390457DOI 10.1016/j.pathophys.2012.02.005PUB-22421507

Rights unknown

Source link

PubMed tag: Review · 2002

Factor VII activating protease (FSAP): a novel protease in hemostasis.

Römisch et al. 2002Biological chemistrycited by 51

PMID 12437095DOI 10.1515/bc.2002.121PUB-12437095

Full text at the publisher

Publisher page

PubMed tag: Comparative Study · 1999

Detection of a novel plasma serine protease during purification of vitamin K-dependent coagulation factors.

Hunfeld et al. 1999FEBS letterscited by 45

PMID 10456326DOI 10.1016/s0014-5793(99)00959-xPUB-10456326

Rights unknown

Source link

PubMed tag: none · 2000

Activation of proPHBSP, the zymogen of a plasma hyaluronan binding serine protease, by an intermolecular autocatalytic mechanism.

Etscheid et al. 2000Biological chemistrycited by 42

PMID 11209757DOI 10.1515/bc.2000.150PUB-11209757

Full text at the publisher

Publisher page

PubMed tag: Systematic Review, review-article · 2017

Managing fatigue in sarcoidosis - A systematic review of the evidence.

Atkins et al. 2017Chronic respiratory diseasecited by 34

PMID 27507833PMC5720218DOI 10.1177/1479972316661926PUB-27507833

Rights unknown

Source link

PubMed tag: Review · 2014

ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

van Velzen et al. 2014Expert opinion on investigational drugscited by 32

PMID 24555851DOI 10.1517/13543784.2014.892072PUB-24555851

Full text at the publisher

Publisher page

PubMed tag: none · 2002

The hyaluronan-binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykinin.

Etscheid et al. 2002Biological chemistrycited by 30

PMID 12452440DOI 10.1515/bc.2002.184PUB-12452440

Rights unknown

Source link

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Cibinetide (ARA-290) studies: 63 papers with results

Page 1 of 2

Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.
Culver DA · Investigative ophthalmology & visual science · 2017
Randomized controlled trial · 8 results
Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action.
Cerit H · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015
Randomized controlled trial · 7 results
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.
Heij L · Molecular medicine (Cambridge, Mass.) · 2012
Randomized controlled trial · 7 results
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.
Lois N · Journal of clinical medicine · 2020
Non-randomized trial · 8 results
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
Brines M · Molecular medicine (Cambridge, Mass.) · 2015
Other design · 5 results
Treatment of mild traumatic brain injury with an erythropoietin-mimetic peptide.
Robertson CS · Journal of neurotrauma · 2013
Animal study (in vivo) · rat · 4 results
Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy.
McVicar CM · Diabetes · 2011
Animal study (in vivo) · rat · 7 results
The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model.
Pulman KG · Neuroscience · 2013
Animal study (in vivo) · rat · 6 results
ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury.
van Rijt WG · Journal of translational medicine · 2013
Animal study (in vivo) · pig · 4 results
Co-delivery of a growth factor and a tissue-protective molecule using elastin biopolymers accelerates wound healing in diabetic mice.
Devalliere J · Biomaterials · 2017
Animal study (in vivo) · mouse · 6 results
Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns.
Bohr S · Proceedings of the National Academy of Sciences of the United States of America · 2013
Animal study (in vivo) · mouse · 4 results
ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.
Swartjes M · Anesthesiology · 2011
Animal study (in vivo) · mouse and rat · 4 results
A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.
Ahmet I · Molecular medicine (Cambridge, Mass.) · 2011
Animal study (in vivo) · rat · 9 results
Neuroprotection with an erythropoietin mimetic peptide (pHBSP) in a model of mild traumatic brain injury complicated by hemorrhagic shock.
Robertson CS · Journal of neurotrauma · 2012
Animal study (in vivo) · rat · 4 results
A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock.
Patel NS · Molecular medicine (Cambridge, Mass.) · 2011
Animal study (in vivo) · rat · 12 results
ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.
Swartjes M · Molecular pain · 2014
Animal study (in vivo) · rat · 6 results
Nonerythropoietic Erythropoietin-Derived Peptide Suppresses Adipogenesis, Inflammation, Obesity and Insulin Resistance.
Liu Y · Scientific reports · 2015
Animal study (in vivo) · mouse · 10 results
Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia.
Schmidt RE · Experimental neurology · 2011
Animal study (in vivo) · mouse · 6 results
A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets.
Watanabe M · Transplantation · 2016
Animal study (in vivo) · mouse · 10 results
Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus.
Huang B · Journal of cellular and molecular medicine · 2018
Animal study (in vivo) · mouse · 11 results
The erythropoietin-derived peptide mimetic pHBSP affects cellular and cognitive consequences in a rat post-status epilepticus model.
Seeger N · Epilepsia · 2011
Animal study (in vivo) · rat · 5 results
ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors' Angiogenic Potential and Homing Ability.
Hache G · Shock (Augusta, Ga.) · 2016
Animal study (in vivo) · mouse · 7 results
Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat.
Chen H · Journal of neuroimmunology · 2014
Animal study (in vivo) · rat · 18 results
The Role of Macrophage Efferocytosis in the Pathogenesis of Apical Periodontitis.
Guan X · International journal of molecular sciences · 2024
Animal study (in vivo) · 2 results
Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.
Nairz M · Scientific reports · 2017
Animal study (in vivo) · mouse · 6 results
Ketamine does not produce relief of neuropathic pain in mice lacking the β-common receptor (CD131).
Swartjes M · PloS one · 2013
Animal study (in vivo) · mouse · 8 results
The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic.
O'Leary OE · Experimental eye research · 2019
Animal study (in vivo) · mouse · 6 results
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.
Al-Onaizi MA · Brain, behavior, and immunity · 2022
Animal study (in vivo) · mouse · 10 results
Renoprotective capacities of non-erythropoietic EPO derivative, ARA290, following renal ischemia/reperfusion injury.
van Rijt WG · Journal of translational medicine · 2013
Animal study (in vivo) · rat · 9 results
Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes.
Bitto A · Biochimica et biophysica acta. Molecular basis of disease · 2018
Animal study (in vivo) · mouse · 8 results
Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress-Induced Depression-Like Behavior and Inflammation in Mice.
Xu G · Frontiers in pharmacology · 2022
Animal study (in vivo) · mouse · 5 results
ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.
Zhang W · Peptides · 2016
Animal study (in vivo) · 2 results
ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats.
Muller C · Molecular medicine (Cambridge, Mass.) · 2016
Animal study (in vivo) · rat · 14 results
Erythropoietin-Derived Peptide Protects Against Acute Lung Injury After Rat Traumatic Brain Injury.
Liu Y · Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2017
Animal study (in vivo) · rat · 8 results
Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke.
Wang RL · CNS neuroscience & therapeutics · 2024
Animal study (in vivo) · mouse · 4 results
Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation.
Yao M · Cell transplantation · 2021
Animal study (in vivo) · mouse · 7 results
Microglial EPOR Contribute to Sevoflurane-induced Developmental Fine Motor Deficits Through Synaptic Pruning in Mice.
He D · Neuroscience bulletin · 2024
Animal study (in vivo) · mouse · 3 results
The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice.
Awida Z · International journal of molecular sciences · 2021
Animal study (in vivo) · mouse · 4 results
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand.
Yao M · Transplantation · 2020
Animal study (in vivo) · mouse · 6 results
Targeting the innate repair receptor axis via erythropoietin or pyroglutamate helix B surface peptide attenuates hemolytic-uremic syndrome in mice.
Dennhardt S · Frontiers in immunology · 2022
Animal study (in vivo) · mouse · 5 results
Assessment of the Nephroprotective Properties of the Erythropoietin Mimetic Peptide and Infliximab in Kidney Ischemia-Reperfusion Injury in Rats.
Netrebenko AS · Archives of Razi Institute · 2021
Animal study (in vivo) · rat · 6 results
ARA290 Attenuates Apical Periodontitis via SIRT1/NF-κB/IL-1β Pathway Modulation.
Wang Y · International dental journal · 2025
Animal study (in vivo) · mouse · 10 results
ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury.
Liu G · European journal of pharmacology · 2025
Animal study (in vivo) · rat · 5 results
A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan.
Winicki NM · Frontiers in cardiovascular medicine · 2022
Animal study (in vivo) · fischer 344 x brown norway rat · 12 results
Erythropoietin Mimetic Peptide (pHBSP) Corrects Endothelial Dysfunction in a Rat Model of Preeclampsia.
Korokin M · International journal of molecular sciences · 2020
Animal study (in vivo) · rat · 9 results
Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.
Alasousi D · Neurobiology of disease · 2026
Animal study (in vivo) · mouse · 3 results
Immunosuppressive effects of erythropoietin on human alloreactive T cells.
Cravedi P · Journal of the American Society of Nephrology : JASN · 2014
In vitro (cells) · 2 results
Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells.
Bohr S · Journal of molecular medicine (Berlin, Germany) · 2015
In vitro (cells) · mouse · 7 results
Potential role of erythropoietin receptors and ligands in attenuating apoptosis and inflammation in critical limb ischemia.
Joshi D · Journal of vascular surgery · 2014
In vitro (cells) · mouse · 4 results
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress.
Shokrzadeh M · Toxicology in vitro : an international journal published in association with BIBRA · 2020
In vitro (cells) · 5 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	Four orphan designations to Araim Pharmaceuticals, all with status Designated and none approved: 2009-09-18 prevention of delayed graft function after renal transplant; 2011-09-13 treatment of neuropathic pain in patients with sarcoidosis; 2016-06-13 treatment of sarcoidosis; 2016-06-13 treatment to increase survival and improve functioning of pancreatic islets after transplantation. No Drugs@FDA record (openFDA drugsfda searches for cibinetide on 2026-10-09 returned no matches). The status 'investigational' rests on the registered trials and the orphan designations; no IND record was checked.	9 Oct 2026	fda.gov (opens in a new tab)
EU	EMA	No EU marketing authorisation. Two orphan designations with status Positive in the EMA data file: EU/3/13/1191 (2013-10-07, treatment of sarcoidosis) and EU/3/16/1721 (2016-08-29, prevention of graft loss in pancreatic islet transplantation), both for 'L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser (cibinetide)'. Checked in the EMA medicines file (timestamp 2026-10-09T06:23:44Z; no match) and the orphan designations file (timestamp 2026-10-09T06:32:20Z).	9 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Banned in sport (WADA S2.1.5) The name cibinetide is not in the 2026 or 2027 list index.	2026 List	wada-ama.org (opens in a new tab)
World (WADA 2027 list)	Note	The 2027 list keeps the S2.1.5 wording and still does not name cibinetide.	9 Oct 2026	wada-ama.org (opens in a new tab)

Safety outcomes

10 safety results for Cibinetide (ARA-290).

Human evidence· 4

In patients with sarcoidosis and small fiber neuropathy symptoms, clinical and laboratory assessments raised no safety concerns with ARA‑290.
Randomized controlled trialn = 22
In adults with diabetic macular edema, no serious adverse events or reactions were seen with 12 weeks of cibinetide.
Non-randomized trialn = 9
In adults with diabetic macular edema, no anti-cibinetide antibodies were seen after 12 weeks of cibinetide.
Non-randomized trialn = 9
In adults with type 2 diabetes and painful neuropathy, ARA‑290 4 mg daily for 28 days raised no potential safety issues.
Other designn not reported

Animal evidence· 6

In diabetic rats and nondiabetic controls, pHBSP or scrambled peptide treatment did not alter hematocrit.
Animal study (in vivo)Ratn = 24
In high-fat diet-fed mice, pHBSP improved obesity, insulin resistance and adipose inflammation without stimulating hematopoiesis.
Animal study (in vivo)mouse
In SLE mice, ARA290 did not induce haematopoiesis during treatment.
Animal study (in vivo)mouse
In normal and β-common receptor knockout mice, ARA290 did not produce psychomotor side effects.
Animal study (in vivo)mouse
In stressed mice, ARA290 had marginal effects on peripheral blood hemoglobin and red cells.
Animal study (in vivo)mouse
In type 2 diabetic GK rats, ARA290 did not affect hematocrit.
Animal study (in vivo)rat

Doses studied · 31

The doses that these studies used. They are not recommendations.

1 mg/dayHuman
Species
human
Route
Not reported
Duration
28 days
Design
Randomized controlled trial
4 mg/dayHuman
Species
human
Route
Not reported
Duration
28 days
Design
Randomized controlled trial
8 mg/dayHuman
Species
human
Route
Not reported
Duration
28 days
Design
Randomized controlled trial
1, 4 and 8 mg/dayHuman
Species
human
Route
Not reported
Duration
28 days
Design
Randomized controlled trial · n = 64
2 mgHuman
Species
human
Route
Not reported
Duration
Not reported
Design
Randomized controlled trial · n = 36
2 mg three times weeklyHuman
Species
human
Route
intravenous
Duration
4 weeks
Design
Randomized controlled trial · n = 22

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
1 mg/day	Human	human	Not reported	28 days	Randomized controlled trial
4 mg/day	Human	human	Not reported	28 days	Randomized controlled trial
8 mg/day	Human	human	Not reported	28 days	Randomized controlled trial
1, 4 and 8 mg/day	Human	human	Not reported	28 days	Randomized controlled trial · n = 64
2 mg	Human	human	Not reported	Not reported	Randomized controlled trial · n = 36
2 mg three times weekly	Human	human	intravenous	4 weeks	Randomized controlled trial · n = 22

6 of 31 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000043
Peptide version: 8
Peptide hash: 68dd19b759874e1a…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 256641
22 Oct 2026UpdatedData version 254490
21 Oct 2026UpdatedData version 213595
14 Oct 2026UpdatedData version 194677
13 Oct 2026UpdatedData version 173527
12 Oct 2026UpdatedData version 165102

For developers

curl -s https://pepbank.io/v1/briefs/ara-290

Evidence summary for Cibinetide (ARA-290): counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
NeuroprotectionNervous system and cognition	Human: 7 results from 2 studies: 3 increase, 2 no significant change, 2 not reported. Strongest design: Randomized controlled trial	Animal: 24 results from 9 studies: 6 increase, 10 decrease, 6 no significant change, 2 not reported. Strongest design: Animal study (in vivo)	Lab: 8 results from 1 study: 4 increase, 4 decrease. Strongest design: In vitro (cells)	No results	39
PainNervous system and cognition	Human: 6 results from 3 studies: 3 decrease, 2 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 14 results from 5 studies: 9 decrease, 5 no significant change. Strongest design: Animal study (in vivo)	No results	No results	20
Vision and retinaEye	Human: 6 results from 1 study: 1 increase, 4 no significant change, 1 mixed. Strongest design: Non-randomized trial	Animal: 2 results from 1 study: 1 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	8
Anxiety and moodMental health and mood	Human: 5 results from 2 studies: 1 decrease, 4 no significant change. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	6
Cognition and memoryNervous system and cognition	Human: 3 results from 1 study: 2 increase, 1 no significant change. Strongest design: Randomized controlled trial	Animal: 7 results from 5 studies: 1 increase, 4 decrease, 2 no significant change. Strongest design: Animal study (in vivo)	No results	No results	10
Adverse eventsWhole body	Human: 3 results from 3 studies: 3 no significant change. Strongest design: Randomized controlled trial	Animal: 6 results from 6 studies: 6 no significant change. Strongest design: Animal study (in vivo)	No results	No results	9
Exercise and physical functionWhole body	Human: 2 results from 1 study: 1 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	3
Immune responseKidney and urinary	Human: 1 result from 1 study: 1 no significant change. Strongest design: Non-randomized trial	Animal: 16 results from 4 studies: 5 increase, 9 decrease, 1 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 9 results from 6 studies: 2 increase, 5 decrease, 2 no significant change. Strongest design: Ex vivo tissue	No results	26
Glycemic controlMetabolic and weight	Human: 1 result from 1 study: 1 decrease. Strongest design: Other design	Animal: 17 results from 7 studies: 8 increase, 4 decrease, 4 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 3 results from 2 studies: 3 increase. Strongest design: Ex vivo tissue	No results	21
LipidsMetabolic and weight	Human: 1 result from 1 study: 1 not reported. Strongest design: Other design	No results	No results	No results	1
Inflammation markersSkin and wound	No results	Animal: 68 results from 25 studies: 2 increase, 51 decrease, 9 no significant change, 2 mixed, 4 not reported. Strongest design: Animal study (in vivo)	Lab: 24 results from 9 studies: 5 increase, 19 decrease. Strongest design: Ex vivo tissue	No results	92
Kidney functionKidney and urinary	No results	Animal: 21 results from 7 studies: 3 increase, 10 decrease, 5 no significant change, 3 not reported. Strongest design: Animal study (in vivo)	Lab: 8 results from 1 study: 2 increase, 6 decrease. Strongest design: In vitro (cells)	No results	29

Outcome group	Human	Animal	Lab	Computer model	Total
NeuroprotectionNervous system and cognition	Human: 7 results from 2 studies: 3 increase, 2 no significant change, 2 not reported. Strongest design: Randomized controlled trial	Animal: 24 results from 9 studies: 6 increase, 10 decrease, 6 no significant change, 2 not reported. Strongest design: Animal study (in vivo)	Lab: 8 results from 1 study: 4 increase, 4 decrease. Strongest design: In vitro (cells)	No results	39
PainNervous system and cognition	Human: 6 results from 3 studies: 3 decrease, 2 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 14 results from 5 studies: 9 decrease, 5 no significant change. Strongest design: Animal study (in vivo)	No results	No results	20
Vision and retinaEye	Human: 6 results from 1 study: 1 increase, 4 no significant change, 1 mixed. Strongest design: Non-randomized trial	Animal: 2 results from 1 study: 1 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	8
Anxiety and moodMental health and mood	Human: 5 results from 2 studies: 1 decrease, 4 no significant change. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	6
Cognition and memoryNervous system and cognition	Human: 3 results from 1 study: 2 increase, 1 no significant change. Strongest design: Randomized controlled trial	Animal: 7 results from 5 studies: 1 increase, 4 decrease, 2 no significant change. Strongest design: Animal study (in vivo)	No results	No results	10
Adverse eventsWhole body	Human: 3 results from 3 studies: 3 no significant change. Strongest design: Randomized controlled trial	Animal: 6 results from 6 studies: 6 no significant change. Strongest design: Animal study (in vivo)	No results	No results	9
Exercise and physical functionWhole body	Human: 2 results from 1 study: 1 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	3
Immune responseKidney and urinary	Human: 1 result from 1 study: 1 no significant change. Strongest design: Non-randomized trial	Animal: 16 results from 4 studies: 5 increase, 9 decrease, 1 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 9 results from 6 studies: 2 increase, 5 decrease, 2 no significant change. Strongest design: Ex vivo tissue	No results	26
Glycemic controlMetabolic and weight	Human: 1 result from 1 study: 1 decrease. Strongest design: Other design	Animal: 17 results from 7 studies: 8 increase, 4 decrease, 4 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 3 results from 2 studies: 3 increase. Strongest design: Ex vivo tissue	No results	21
LipidsMetabolic and weight	Human: 1 result from 1 study: 1 not reported. Strongest design: Other design	No results	No results	No results	1
Inflammation markersSkin and wound	No results	Animal: 68 results from 25 studies: 2 increase, 51 decrease, 9 no significant change, 2 mixed, 4 not reported. Strongest design: Animal study (in vivo)	Lab: 24 results from 9 studies: 5 increase, 19 decrease. Strongest design: Ex vivo tissue	No results	92
Kidney functionKidney and urinary	No results	Animal: 21 results from 7 studies: 3 increase, 10 decrease, 5 no significant change, 3 not reported. Strongest design: Animal study (in vivo)	Lab: 8 results from 1 study: 2 increase, 6 decrease. Strongest design: In vitro (cells)	No results	29

Cibinetide (ARA-290) studies and research data

ARA-290 identity

Targets

Sequence and structure

Sequence

Alignment to Erythropoietin (human)

Properties

Net charge by pH

Composition

3D structure

2D structure

Helical wheel

ARA-290 results by year and outcome

What the studies measured

ARA-290 studies on brain and nerves

ARA-290 studies on pain

ARA-290 studies on eyes

ARA-290 studies on mood, stress and behavior

ARA-290 studies on memory and thinking

ARA-290 studies on side effects

ARA-290 studies on daily life and fitness

ARA-290 studies on immune system and inflammation

ARA-290 studies on blood sugar

ARA-290 studies on cholesterol and blood fats

ARA-290 studies on kidneys and bladder

ARA-290 studies on skin, hair and wounds

ARA-290 studies on heart and blood vessels

ARA-290 studies on receptors and cell signals

ARA-290 studies on bones and joints

ARA-290 studies on survival and serious illness

ARA-290 studies on cells, genes and aging

ARA-290 studies on weight and appetite

ARA-290 studies on liver

ARA-290 studies on muscles and tendons

ARA-290 studies on infections

ARA-290 trials

The Use of ARA290 for the Treatment of Diabetic Macular Oedema

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)

Cognitive and Neural Effects of ARA290

Papers

Studies with results

Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy.

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

Co-delivery of a growth factor and a tissue-protective molecule using elastin biopolymers accelerates wound healing in diabetic mice.

Immunosuppressive effects of erythropoietin on human alloreactive T cells.

Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns.

ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.

A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.

Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.

Neuroprotection with an erythropoietin mimetic peptide (pHBSP) in a model of mild traumatic brain injury complicated by hemorrhagic shock.

ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury.

Multifaceted roles of a bioengineered nanoreactor in repressing radiation-induced lung injury.

A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock.

ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.

More studies

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy.

Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.

Erythropoietin neuroprotection with traumatic brain injury.

Factor VII activating protease (FSAP): a novel protease in hemostasis.

Detection of a novel plasma serine protease during purification of vitamin K-dependent coagulation factors.

Activation of proPHBSP, the zymogen of a plasma hyaluronan binding serine protease, by an intermolecular autocatalytic mechanism.

Managing fatigue in sarcoidosis - A systematic review of the evidence.

ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

The hyaluronan-binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykinin.

Newer studies

Cibinetide (ARA-290) studies: 63 papers with results

Regulatory and safety

Human evidence· 4

Animal evidence· 6

Doses studied · 31

Data and API

Peptide

Latest changes

For developers

Related peptides

ARA-290 results by year and outcome